预防性胰管支架最佳留置时间:多中心随机对照试验
这项多中心随机对照试验比较了ERCP后预防性5-Fr胰管支架留置2周与4周的策略。结果显示,4周组需内镜下取出的比例显著低于2周组(6.6% vs 18.8%),且未增加胰腺炎等并发症。4周留置策略可减少内镜取出需求且安全性良好。
核心结论
- 4周留置策略减少了内镜下支架取出需求,且未增加ERCP后胰腺炎或其他临床相关并发症。
研究设计与样本
- 前瞻性多中心随机对照试验,纳入接受ERCP并放置5-Fr单猪尾无凸缘胰管支架的成人患者,按1:1随机分为2周组和4周组。
- 共筛选182例,随机160例,分析156例(2周组80例,4周组76例)。
主要发现
- 研究期间未观察到胰管支架相关性胰腺炎。
临床怎么用
- 对于ERCP术中放置预防性5-Fr单猪尾无凸缘胰管支架的患者,可考虑留置4周而非2周,以减少内镜下支架取出需求。
- 4周留置策略未增加ERCP后胰腺炎风险,但需注意自发性脱落率有升高趋势。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Prophylactic pancreatic duct stent placement is used during endoscopic retrograde cholangiopancreatography to prevent post-endoscopic retrograde cholangiopancreatography pancreatitis and facilitate difficult biliary cannulation; however, the optimal retention duration of prophylactic pancreatic duct stent remains uncertain. This trial compared 2-week vs 4-week pancreatic duct stent retention to determine the strategy that minimizes the need for endoscopic stent removal without compromising safety. METHODS: In this prospective multicenter trial, adults undergoing endoscopic retrograde cholangiopancreatography with placement of a 5-Fr single-pigtail unflanged pancreatic duct stent were randomized in a 1:1 ratio to undergo scheduled assessment at 2 or 4 weeks post-endoscopic retrograde cholangiopancreatography to evaluate pancreatic duct stent retention via abdominal radiography. The primary outcome was the proportion of patients requiring endoscopic stent removal due to confirmed pancreatic duct stent retention. Secondary outcomes included spontaneous stent dislodgment, incidence and severity of post endoscopic retrograde cholangiopancreatography pancreatitis and pancreatic duct stent-associated pancreatitis, and length of hospital stay. RESULTS: Among 182 screened patients, 160 were randomized, and 156 were analyzed (80 in the 2-week group; 76 in the 4-week group). The primary outcome, requirement for endoscopic pancreatic duct stent removal, was significantly lower in the 4-week group than in the 2-week group (6.6% [5/76] vs 18.8% [15/80]; odds ratio, 0.305; 95% confidence interval, 0.105-0.887; P = .030). This was driven by a higher spontaneous dislodgment rate in the 4-week group (92.1% [70/76] vs 81.3% [65/80]; odds ratio, 0.371; 95% confidence interval, 0.136-1.015; P = .061). Post-endoscopic retrograde cholangiopancreatography pancreatitis developed in 10.5% (8/76) of the 4-week group and 15.0% (12/80) of the 2-week group (P = .403), with a median onset of 1 day post-endoscopic retrograde cholangiopancreatography. Post-endoscopic retrograde cholangiopancreatography pancreatitis was predominantly mild, with only 2 moderate cases in each group. No cases of pancreatic duct stent-associated pancreatitis were observed during the study period. CONCLUSIONS: A 4-week retention strategy reduced the need for endoscopic stent removal without increasing the incidence of post-endoscopic retrograde cholangiopancreatography pancreatitis or other clinically relevant complications. CLINICALTRIALS: gov, Number: NCT04691674.
引用
- Jang DK, Choi YH, Kim EJ, et al. Optimal Retention Duration of Prophylactic Pancreatic Duct Stents Placed During Endoscopic Retrograde Cholangiopancreatography: A Multicenter Randomized Controlled Trial. Clin Gastroenterol Hepatol. 2026. PMID: 42331078. doi:10.1016/j.cgh.2026.06.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。